Blood Fat and Inflammation Markers After a Fatty Meal in Diabetes and Prediabetes
Studies blood fat responses after a fatty drink in people with prediabetes or diabetes.
Plain-language title generated from the registry record
Registry title: Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.
Key facts
- Where
- Ferrara and Poggio Renatico, ItalySee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT07602023, who can take part
Where in Italy
- University Hospital "Sant'Anna" of FerraraFerrara, ItalyTaking people
- Nucleo di Cure Primarie di Poggio Renatico - Medicina di Gruppo Poggio Rete Salute Via Salvo D'Acquisto, 1/aPoggio Renatico, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Angelina Passaro
- Trial code
- NCT07602023
- Record updated
- 22 May 2026
- Original description
The aim of the study is to evaluate whether the Oral Fat Loading Test (OFLT) determines a different response in terms of the quantity, quality, and kinetics of triglyceride-rich lipoproteins in subjects with T2D, prediabetics, and control subjects, and whether triglyceride-rich lipoproteins and inflammatory cytokines after OFLT are potential early biomarkers of the risk of progression to diabetes and the development of complications in a general practice setting.Read full original descriptionShow less
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.
The aim of the study is to evaluate whether the Oral Fat Loading Test (OFLT) determines a different response in terms of the quantity, quality, and kinetics of triglyceride-rich lipoproteins in subjects with T2D, prediabetics, and control subjects, and whether triglyceride-rich lipoproteins and inflammatory cytokines after OFLT are potential early biomarkers of the risk of progression to diabetes and the development of complications in a general practice setting.
To address these questions, a hybrid cohort study was designed by identifying three groups of subjects: T2D and prediabetics (exposed and near-exposed) and control subjects (unexposed).
Inclusion: Males and females aged 50-70 years; BMI between 25-30 kg/m2; HbA1c ≤7% for T2D; HbA1c ≤6.5% for prediabetes; HbA1c ≤5.7% for controls; Signed Project Information and Informed Consent Form; Signed Data Processing Consent Form.
Exclusion: Lipid-lowering therapy with ezetimibe, fenofibrate, omega-3 fatty acids, or other drugs that can interfere with lipoprotein absorption and metabolism; Patients on insulin therapy; Patients on stable therapy for less than 3 months; All acute and chronic conditions that, in the opinion of the investigators, may cause bias; Hospitalization for acute illness or major surgery in the last 6 months; Allergy or intolerance to one or more components of the meal used in the protocol; Chronic Kidney Disease (CKD) with estimated glomerular filtration rate (eGFR) <60 ml/min and renal impairment (e.g., uACR ≥30 mg/mmol) for 3 months or more; Secondary or syndromic forms of obesity; Pregnancy or breastfeeding; Habitual consumption of alcoholic beverages (>20 g/day for females and >30 g/day for males) or unwillingness to abstain from alcoholic beverages during the study run-in period; All subjects who do not consent to participate in the study.